Psychedelic Medicine Sees Promise in Psilocybin and Ibogaine

Psilocybin and ibogaine are framed as promising psychedelic candidates within a fast-moving industry and medical research landscape. The newsletter positions psychedelic developments as a response to unmet mental health needs, referencing major depressive disorder prevalence and limited response rates to existing treatments. The focus is on recent news in psychedelics and what emerging clinical and commercial momentum could mean for future therapies.